2021•Unpublished venueRequires access

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam M. Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Nathan Hale Fowler, Tapan Mahendra Kadia, Marina Y Konopleva, Yesid Alvarado, Musa E. Yilmaz, Courtney Denton Dinardo, Prithviraj Bose, Maro N. Ohanian, Naveen Pemmaraju, Elias Joseph Jabbour, Rashmi Kanagal‐Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A. Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole D. Cruz, Ana B. Ayala, William K. Plunkett, Hagop M. Kantarjian, Varsha V. Gandhi, William G. Wierda

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Venetoclax, Ibrutinib, Chronic lymphocytic leukemia, Medicine, Leukemia, Oncology, Internal medicine